Highest development stage: Approved by FDA in 1964

Development status: Approved, off patent

Gram-positive activity

Mechanism of Action/Target pathogen: Interferes with bacterial cell wall synthesis by competitively inhibiting two enzymes, L-alanine racemase and D-alanine:D-alanine ligase, thereby impairing peptidoglycan formation

Additional information: Natural compound produced by Streptomyces. Used in the treatment of drug resistant tuberculosis